Skip to main content
SpringerLink
Log in

Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Matrix metalloproteinases (MMPs) have been implicated in the process of tumor invasion and metastasis formation. Thus, we determined the expression of MMPs in various primary and metastatic spinal tumors in order to assess the role of these enzymes in spinal invasion. MMP expression was examined by immuno-histochemical localization, and quantitative evaluation of MMP protein content was determined by enzyme-linked immunosorbant assay (ELISA) and Western blotting. MMP enzyme activity was determined by gelatin zymography. Lung carcinomas and melanomas metastatic to the spine were shown to have higher levels of MMP-9 activity than those of breast, thyroid, renal metastases and primary spinal tumors. Immunohistochemical analysis revealed similar difference in expression of MMP-9 in tissue samples. When the tissue samples were subjected to gelatin zymography for examination of MMP-2 and MMP-9 activity and to ELISA and Western blotting for quantitative estimation of protein content, the most striking results were obtained for lung carcinomas and melanomas relative to the other tumors. Lung carcinomas and melanomas metastatic to the spine had considerably higher levels of MMP-9 activity than those of primary spinal tumor or breast, thyroid, and renal carcinoma metastases. Within the metastatic tumor category, neoplasms that are known to be associated with the shortest overall survival rates and most aggressive behavior, such as lung carcinomas and melanomas, had the highest levels of MMP-2 and MMP-9 activity compared to those less aggressive metastatic tumors such as breast, renal cell, and thyroid carcinomas. Our results suggest that MMPs may contribute to the metastases to the spinal column, and overexpression of these enzymes may correlate with enhanced invasive properties of both primary and metastatic spinal tumors.© Kluwer Academic Publishers 1998

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sundaresan N, Galicich JH, Chu FC and Huvos AG, 1979, Spinal chordomas. J Neurosurg, 50, 312-19.

    Google Scholar 

  2. Black P, 1979, Spinal metastasis: current status and recommended guidelines for management. Neurosurgery, 5, 726-46.

    Google Scholar 

  3. Harrington KD, 1986, Metastatic disease of the spine. J Bone Joint Surg Am, 68, 1110-15.

    Google Scholar 

  4. Kostuik JP and Weinstein JN, 1991, Differential diagnosis and surgical treatment of metastastic spine tumors. In: Frymoyer JW, ed: The Adult Spine: Principles and Practice.New York: Raven Press, 861-88.

    Google Scholar 

  5. Cummings BJ, Esses S and Harwood AR, 1982, The treatment of chordomas. Cancer Treat Rev, 9, 299-311.

    Google Scholar 

  6. Rich TA, Schiller A, Suit HD and Mankin HJ, 1985, Clinical and pathologic review of 48 cases of chordoma. Cancer, 56, 182-7.

    Google Scholar 

  7. Komiya S, Inoue A, Nakashima M, et al.1986, Prognostic factors in giant cell tumor of bone. A modified histological grading system useful as a guide to prognosis. Arch Orthop Trauma Surg, 105, 67-72.

    Google Scholar 

  8. Nicholson GL, 1989, Metastastic cell interactions with endothelium, basement membrane and tissue. Curr Opin Cell Biol, 1, 1009-19.

    Google Scholar 

  9. Matrisian LM, 1992, The matrix degrading metalloproteinases. Bioessays, 14, 455-63.

    Google Scholar 

  10. Nagase H, Ogata Y, Suzuki K, et al.1991, Substrate specificities and activation mechanisms of matrix metalloproteinases. Biochem Soc Trans, 19, 715-18.

    Google Scholar 

  11. Stearns ME and Wang M, 1993, Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res, 53, 878-83.

    Google Scholar 

  12. Pyke C, Ralfkiaer E, Tryggvason D and Dano K, 1993, Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol, 142, 359-65.

    Google Scholar 

  13. Monteagudo C, Merino MJ, San-Juan J, et al.1990, Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol, 136, 585-92.

    Google Scholar 

  14. Pyke C, Ralfkiaer E, Huhtala P, et al.1992, Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situhybridization. Cancer Res, 52, 1336-41.

    Google Scholar 

  15. Koshikawa N, Yasumitsu H, Umeda M and Miyazaki K, 1992, Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines. Cancer Res, 52, 5046-53.

    Google Scholar 

  16. Schwartz GK, Wang H, Lampen N, et al,1994, Defining the invasive phenotype of proximal gastric cancer cells. Cancer, 73, 22-27.

    Google Scholar 

  17. Taniguchi S, Iwamura T and Katsuki T, 1992, Correlation between spontaneous metastatic potential and type I collagenolytic activity in a human pancreatic cancer cell line (SUIT-2) and sublines. Clin Exp Metastasis, 10, 259-66.

    Google Scholar 

  18. Zucker S, Lysik RM, Wieman J, et al.1985, Diversity of human pancreatic cancer cell proteinases: role of cell membrane metalloproteinases in collagenolysis and cytolysis. Cancer Res, 45, 6168-78.

    Google Scholar 

  19. Liotta LA, Steeg PS and Stetler-Stevenson WG, 1991, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-36.

    Google Scholar 

  20. Schultz R, Silberman S, Persky G, et al.1988, Inhibition by human recombinant tissue inhibitor of metalloproteinases of human aminion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res, 48, 5539-45.

    Google Scholar 

  21. Nakajima M, Welch D, Belloni PN and Nicholson GL, 1987, Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res, 47, 4869-76.

    Google Scholar 

  22. Liotta LA, Tryggvason K and Garbisa S, 1980, Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 284, 67-68.

    Google Scholar 

  23. Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, et al.1985, Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst, 75, 99-103.

    Google Scholar 

  24. Rao VH, Singh RK and Bridge JA, et al.1997, Regulation of MMP-9 (92 kDa type IV collagenase/gelatinase B) expression in stromal cells of human giant cell tumor of bone. Clin Exp Metastasis, 15, 400-9.

    Google Scholar 

  25. Rao VH, Bridge JA and Neff JR, et al.1995, Expression of 72-kDa and 92-kDa Type IV collagenases from human giant cell tumor of bone. Clin Exp Metastasis, 13, 420-6.

    Google Scholar 

  26. Sasaguri Y, Komiya S and Sugama K, et al.1992, Production of matrix metalloproteinases 2 and 3 (stromelysin) by stromal cells of giant cell tumor of bone. Am J Pathol, 141, 611-21.

    Google Scholar 

  27. Rao JS, Steck PA, Mohanam S, et al.1993, Elevated levels of Mr 92,000 type IV collagenase in human brain tumors. Cancer Res, 53, 2208-11.

    Google Scholar 

  28. Liotta LA and Stetler-Stevenson WG, 1991, Tumor invasion and metastasis: an imbalance of positive and negative regulators. Cancer Res, 51, 50543-95.

    Google Scholar 

  29. Ballin M, Gomez DE, Sinha CC and Thorgeirsson UP, 1988, RAS Oncogene mediated induction of a 92 Kda metalloproteinase; strong correlation with the malignant phenotype. Biochem Biophy Res Commun, 154, 832-8.

    Google Scholar 

  30. Stetler-Stevenson WG, 1990, Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev, 9, 289-303.

    Google Scholar 

  31. Testa JE, 1992, Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, Hep-3, is accompanied by increased expression of tissue inhibitor of metalloproteinase 2. Cancer Res, 52, 5597-603.

    Google Scholar 

  32. Alvarez O, Carmichael D and DeClerck Y, 1990, Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst, 82, 589-95.

    Google Scholar 

  33. Welgus HG, Jeffrey JJ, Eisen AZ, et al.1985, Human skin fibroblast collagenase: interaction with substrate and inhibitor. Collagen Related Res, 5, 167-79.

    Google Scholar 

  34. Tsuchiya Y, Sato H and Endo Y, et al.1993, Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res, 53, 1397-1402.

    Google Scholar 

  35. DeClerck YA, Perez N, Shimada H, et al.1992, Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res, 52, 701-8.

    Google Scholar 

  36. Okada Y, Gonoji Y and Naka K, et al.1992, Matrix metalloproteinase 9 (92-KDa gelatinase/Type IV collagenase) from the HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem, 267, 21712-19.

    Google Scholar 

  37. Okada Y, Naka K and Kawamura K, et al.1995, Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest, 72, 311-22.

    Google Scholar 

  38. Lang FF and Sawaya R, 1996, Surgical management of cerebral metastases. Neurosurg Clin N Am, 7, 459-84.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA

    Ziya L Gokaslan, Shravan K Chintala, Julie E York, Venkaiah Boyapati, Sushma Jasti, Raymond Sawaya, Garth L Nicolson & Jasti S Rao

  2. The Institute for Molecular Medicine, Huntington Beach, CA, 92649, USA

    Gregory Fuller & David M Wildrick

Authors
  1. Ziya L Gokaslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shravan K Chintala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julie E York
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Venkaiah Boyapati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sushma Jasti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Raymond Sawaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gregory Fuller
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David M Wildrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Garth L Nicolson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jasti S Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gokaslan, Z.L., Chintala, S.K., York, J.E. et al. Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin Exp Metastasis 16, 721–728 (1998). https://doi.org/10.1023/A:1006580728338

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006580728338

Search

Navigation